|1.||Vllasaliu, Driton: 1 article (01/2015)|
|2.||Govori, Valbona: 1 article (01/2015)|
|3.||Norata, Giuseppe Danilo: 1 article (01/2015)|
|4.||Shala, Aida: 1 article (01/2015)|
|5.||Krasniqi, Shaip: 1 article (01/2015)|
|6.||Daci, Armond: 1 article (01/2015)|
|7.||Beretta, Giangiacomo: 1 article (01/2015)|
|8.||Tanaka, Yoji: 1 article (01/2013)|
|9.||Ohno, Kikuo: 1 article (01/2013)|
|10.||Nariai, Tadashi: 1 article (01/2013)|
|1.||Body Weight (Weight, Body)
01/01/2015 - "Plasma concentrations of CBZ, carbamazepine-10,11-epoxide (CBZE) and carbamazepine-10,11-trans dihydrodiol (CBZD) were determined by HPLC-UV-DAD and adjusted for CBZ dosage/kg of body weight. "
09/01/1988 - "The steady-state serum level profiles of carbamazepine (CBZ) and its metabolites CBZ-10,11-epoxide (CBZE) and 10,11-dihydro-CBZ-10,11-diole (CBZD) during 24 h in 21 of 48 patients treated with daily single doses of 8.4 (+/- 2.4) mg/kg body weight CBZ-SR were determined by a high-performance liquid chromatography procedure. "
|2.||Diffuse Axonal Injury
|3.||Trigeminal Neuralgia (Tic Douloureux)
01/01/1985 - "The urinary excretion (as a percentage of the administered dose) of 9-hydroxymethyl-10-carbamoyl-acridan (9-OH-CBZ) was also increased, whereas the excretion of 2-OH-CBZ and 3-OH-CBZ in groups 2 and 3 were decreased in comparison with group 1. As it has been suggested that 9-OH-CBZ is formed from carbamazepine-10,11-epoxide (CBZ-E) or trans-CBZ-diol, the formation of 9-OH-CBZ was investigated in 3 patients with trigeminal neuralgia treated with carbamazepine or CBZ-E as monotherapy on separate occasions. "
|4.||Brain Injuries (Brain Injury)
|5.||Brain Concussion (Cerebral Concussion)